Main Article Content
Abstract
The aim of the present investigation was to formulate, optimize, and characterize Gum Ghatti (GG) nanoparticles containing Irinotecan for cancer therapy. The nanoparticles were formed using a solvent evaporation technique involving aqueous and organic phases. The formulation was optimized by adjusting various process and formulation parameters. The analytical method was developed using acetonitrile and phosphate buffer saline. Different organic solvents and various surfactants were tested to optimize the nanoparticulate formulation. The size range and zeta potential were measured using a Malvern zetasizer. Lyophilization was carried out using two different methods, with the maximum drug entrapment percentage found to be 35.2%. The in vitro drug release of Irinotecan nanoparticles was assessed using the dialysis method in phosphate buffer saline at pH 7.4. The in vitro drug release demonstrated sustained drug release over 24 hours. Therefore, Irinotecan-loaded GG nanoparticles have potential as a drug delivery system. Furthermore, they may be useful for site-specific drug delivery, as their small size may allow them to reach extravascular target sites through the leaky endothelium of inflamed and cancerous areas.